Lineage Cell Therapeutics (LCTX) Preferred Shares (2014 - 2015)
Lineage Cell Therapeutics' (LCTX) quarterly Preferred Shares came in at $3.5 million in Q2 2015, little changed year-on-year from $3.5 million in Q2 2014, and little changed quarter-over-quarter from $3.5 million in Q1 2015.
Lineage Cell Therapeutics (LCTX) Preferred Shares (2014 - 2015) Analysis & Trends
Lineage Cell Therapeutics' Preferred Shares history runs 2 years deep, the most recent figure standing at $3.5 million for Q2 2015.
- On a quarterly basis, Preferred Shares changed 0.0% year-over-year to $3.5 million in Q2 2015; TTM through Jun 2015 was $3.5 million, a 0.0% change from a year earlier, with the FY2014 full-year figure at $3.5 million, changed N/A from the prior year.
- Preferred Shares steadied at $3.5 million in Q2 2015 per LCTX's latest filing, from $3.5 million in the prior quarter.
- Across five years, Preferred Shares topped out at $3.5 million in Q1 2014 and bottomed at $3.5 million in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 3.50 Mn |
| Mar 31, 2015 | 3.50 Mn |
| Dec 31, 2014 | 3.50 Mn |
| Sep 30, 2014 | 3.50 Mn |
| Jun 30, 2014 | 3.50 Mn |
| Mar 31, 2014 | 3.50 Mn |